Circulating tumor DNA (ctDNA) clearance of EGFR mutation—that is, detectable mutation at baseline that became undetectable or dropped below a predetermined threshold—appears to be predictive of extended progression-free survival for patients with EGFR-mutant, MET-amplified non–small cell lung cancer (NSCLC) with…
In a study reported in the Journal of Clinical Oncology, Cao et al found that U.S. adult cancer survivors had higher levels of mobility disability…
A novel single-photon emission computed tomography/computed tomography (SPECT/CT) acquisition method may provide convenient detection of radiopharmaceutical biodistribution and could lead to improved …
A novel MDM2 inhibitor has demonstrated antitumor activity in progressive salivary cancer, particularly adenoid cystic carcinoma, according to data presented at the 2024 Multidisciplinary Head…
Several professional societies have developed evidence-based guidelines on the use of certain biomarkers to help determine which patients with non–small cell lung carcinoma (NSCLC) may…
In a study reported in JAMA Oncology, investigators identified the risk of a second primary breast cancer among survivors of breast cancer diagnosed at age…
Pain, a debilitating consequence of cancer and its treatments, is highly prevalent among patients with advanced cancer.1 Often persistent and undertreated, it is associated with…
On April 18, the U.S. Food and Drug Administration (FDA) approved the tyrosine kinase inhibitor alectinib (Alecensa) for adjuvant treatment after tumor resection in patients…
Researchers have identified a novel screening strategy to improve early detection of pancreatic cancer in high-risk patients.
Natalie S. Callander, MD, of the University of Wisconsin Carbone Cancer Center, discusses advances in the treatment of patients with multiple myeloma, including her commentary…
Investigators have assessed the rate of survival in patients with intellectual and developmental disabilities diagnosed with breast cancer, colorectal cancer, or lung cancer.
